Evidence map›Paper›PMID 39134702›Full record

ArticleScientific reports2024

Virtual crossmatching reveals upregulation of placental HLA-Class II in chronic histiocytic intervillositis.

Chloe A Brady, Laura B Ford, Chloe Moss, Zhiyong Zou, Ian P Crocker, Alexander E P Heazell

Abstract read
In one paragraph

Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Understanding a Potential Role for the NLRP3 Inflammasome in Placenta-Mediated Pregnancy Complications.American journal of reproductive immunology (New York, N.Y. : 1989) · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Chloe A BradyTommy's Maternal and Fetal Health Research Centre, St Mary's Hospital, The University of Manchester, Manchester, UK. chloe.brady@manchester.ac.uk.ORCID 0000-0002-7671-2966
Laura B FordTransplantation Laboratory, Manchester Royal Infirmary, Manchester University NHS Foundation Trust, Manchester, UK.
Chloe MossTommy's Maternal and Fetal Health Research Centre, St Mary's Hospital, The University of Manchester, Manchester, UK.ORCID 0009-0004-6712-5796
Zhiyong ZouTommy's Maternal and Fetal Health Research Centre, St Mary's Hospital, The University of Manchester, Manchester, UK.ORCID 0000-0002-2551-1742
Ian P CrockerTommy's Maternal and Fetal Health Research Centre, St Mary's Hospital, The University of Manchester, Manchester, UK.
Alexander E P HeazellTommy's Maternal and Fetal Health Research Centre, St Mary's Hospital, The University of Manchester, Manchester, UK.ORCID 0000-0002-4303-7845

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic histiocytic intervillositis (CHI) is a recurrent placental lesion where maternal macrophages infiltrate the intervillous space. Its cause is unknown, though due to similarities to rejected allografts one hypothesis is that CHI represents maternal-fetal rejection. Here, virtual crossmatching was applied to healthy pregnancies and those with a history of CHI. Anti-HLA antibodies, measured by Luminex, were present in slightly more controls than CHI (8/17 (47.1%) vs 5/14 (35.7%)), but there was no significant difference in levels of sensitisation or fetal specific antibodies. Quantification of immunohistochemical staining for HLA-Class II was increased in syncytiotrophoblast of placentas with CHI (Grade 0.44 [IQR 0.1-0.7]) compared to healthy controls (0.06 [IQR 0-0.2]) and subsequent pregnancies (0.13 [IQR 0-0.3]) (P = 0.0004). HLA-Class II expression was positively related both to the severity of CHI (r = 0.67) and C4d deposition (r = 0.48). There was no difference in overall C4d and HLA-Class I immunostaining. Though increased anti-HLA antibodies were not evident in CHI, increased expression of HLA-Class II at the maternal-fetal interface suggests that they may be relevant in its pathogenesis. Further investigation of antibodies immediately after diagnosis is warranted in a larger cohort of CHI cases to better understand the role of HLA in its pathophysiology.

Indexed as

Histocompatibility Antigens Class IIAdultChorionic VilliChronic DiseaseFemaleHumansPlacentaPlacenta DiseasesPregnancyTrophoblastsUp-RegulationHistocompatibility Antigens Class II

Identifiers

PMID39134702
PMCPMC11319473

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.